Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2020

View Archived Issues

Thanks for the memories, myelin

Nanogold improves MS symptoms

European Commission approves Vyndaqel for ATTR-CM

FDA approves Procysbi delayed-release oral granules in packets

PT-112 shows promising activity in mCRPC both as monotherapy and in combination with avelumab

AABH as new predictive biomarker for early diagnosis of prostate cancer

ATLAS study of rucaparib in mUC suspended due to lack of activity

Jiangsu Chia Tai Tianqing Pharmaceutical and collaborators patent BRD4 inhibitors

New IDO-1 inhibitors identified at Bristol-Myers Squibb

City of Hope National Medical Center discovers PARG inhibitors

NZP UK, University of Southampton identify FXR agonists

Toll-like receptor 7/8 antagonists identified at Merck KGaA

Improvements seen with olipudase alfa in pediatric patients with acid sphingomyelinase deficiency

Bipolar-like behavior key factor found in iPSCs and mice

miR-27a-3p is a potential therapeutic target in prostate cancer

Novel microglia-specific reporter mouse model based on the TMEM119 microglia marker

Combination of new CD28- and CD3-based bispecific antibodies shows high antitumor activity

CD229-specific CAR T cells with strong activity against multiple myeloma in vitro and in vivo

Axim advances pharmacokinetic study of cannabinoid-based chewing gum with dronabinol

Complete response recorded in first patient treated with optimized MB-106 in phase I/II study

Diasome reports promising outcomes from phase II trial of HDV added to insulin in type 1 diabetes

Zelira's phase Ib/IIa study of ZLT-101 in insomnia meets primary endpoints

Phase II trial of cabiralizumab with nivolumab in advanced pancreatic cancer misses primary endpoint